$HOTH
Hoth Therapeutics, Inc. Stock $hoth

$hoth Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022047409 Filed on August 12, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$864.4K	$237.6K	$1.458M
YoY Change	-2.28%	8.61%	-40.72%
% of Gross Profit
Research & Development	$1.451M	$971.2K	$989.7K
YoY Change	-32.89%	-44.55%	-39.29%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.684M	$2.300M	$2.661M
YoY Change	-17.48%	-28.12%	-37.69%
Operating Profit	-$2.684M	-$2.300M	-$2.661M
YoY Change	-17.48%	-28.12%
Interest Expense	$40.77K	-$377.8K	$47.50K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$40.18K	-$378.0K	$41.69K
YoY Change	-193.77%	391.86%	316.9%
Pretax Income	-$2.644M	-$2.678M	-$2.572M
YoY Change	-19.78%	-18.26%	-39.64%
Income Tax
% Of Pretax Income
Net Earnings	-$2.644M	-$2.678M	-$2.572M
YoY Change	-19.78%	-18.26%	-39.64%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.05	-$0.09	-$2.68
Diluted Earnings Per Share	-$2.05	-$0.09	-$107.3K
COMMON SHARES
Basic Shares Outstanding	32.21M shares	31.03M shares	959.0K shares
Diluted Shares Outstanding	1.288M shares	31.03M shares	959.0K shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.266M	$11.62M	$8.296M
YoY Change	-36.0%	-33.31%	-59.24%
Cash & Equivalents	$8.935M	$11.32M	$6.381M
Short-Term Investments	$330.9K	$304.3K	$1.915M
Other Short-Term Assets	$191.4K	$191.2K	$189.7K
YoY Change	-23.55%	35.22%	5.38%
Inventory
Prepaid Expenses	$191.4K	$191.2K
Receivables
Other Receivables
Total Short-Term Assets	$9.507M	$11.86M	$8.535M
YoY Change	-35.66%	-32.48%	-58.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$387.4K	$387.4K	$410.0K
YoY Change	-5.51%	-5.51%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$387.4K	$387.4K	$410.0K
YoY Change	-5.51%	-15.78%	-10.87%
TOTAL ASSETS
Total Short-Term Assets	$9.507M	$11.86M	$8.535M
Total Long-Term Assets	$387.4K	$387.4K	$410.0K
Total Assets	$9.895M	$12.25M	$8.945M
YoY Change	-34.85%	-32.05%	-57.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$930.9K	$679.4K	$699.8K
YoY Change	-28.47%	-15.59%	20.66%
Accrued Expenses	$52.50K	$49.26K	$126.0K
YoY Change	-82.8%	-88.11%	-30.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.008M	$753.7K	$825.8K
YoY Change	-37.23%	-38.19%	8.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$275.0K	$275.0K	$235.0K
YoY Change	17.02%	17.02%	-18.97%
Total Long-Term Liabilities	$275.0K	$275.0K	$235.0K
YoY Change	17.02%	17.02%	-18.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.008M	$753.7K	$825.8K
Total Long-Term Liabilities	$275.0K	$275.0K	$235.0K
Total Liabilities	$1.283M	$1.029M	$1.061M
YoY Change	-30.31%	-29.27%	2.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.62M	-$38.98M
YoY Change
Common Stock	$129.00	$3.221K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.611M	$11.22M	$7.884M
YoY Change
Total Liabilities & Shareholders Equity	$9.895M	$12.25M	$8.945M
YoY Change	-34.85%	-32.05%	-57.38%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.644M	-$2.678M	-$2.572M
YoY Change	-19.78%	-18.26%	-39.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.389M	-$2.223M	-$2.136M
YoY Change	-11.62%	-19.62%	-21.45%
INVESTING ACTIVITIES
Capital Expenditures	$9.950K	-$51.45K	-$25.00K
YoY Change	-110.86%	-182.85%	-64.29%
Acquisitions
YoY Change
Other Investing Activities	-$10.00	$1.236M	$0.00
YoY Change	-100.0%	-309.14%	-100.0%
Cash From Investing Activities	$9.950K	$1.184M	-$25.00K
YoY Change	-101.72%	-323.97%	-102.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	5.985M
YoY Change	-100.0%	-4521.94%
NET CHANGE
Cash From Operating Activities	-2.389M	-2.223M	-2.136M
Cash From Investing Activities	9.950K	1.184M	-25.00K
Cash From Financing Activities	0.000	5.985M
Net Change In Cash	-2.379M	4.947M	$0.00
YoY Change	-29.66%	-244.25%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.389M	-$2.223M	-$2.136M
Capital Expenditures	$9.950K	-$51.45K	-$25.00K
Free Cash Flow	-$2.399M	-$2.171M	-$2.111M
YoY Change	-8.14%	-23.2%	-20.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38803
	dei	Entity Registrant Name EntityRegistrantName	Hoth Therapeutics, Inc.
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1553794
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Rockefeller Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1039
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10020
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	756-2997
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	HOTH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32211128	shares
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43589471	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11317535	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8538270	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	304327	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1892837	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	191181	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93972	usd
CY2022Q2	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	50000	usd
CY2021Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	50000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	11863043	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10575079	usd
CY2022Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	387400	usd
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	410000	usd
CY2022Q2	us-gaap	Assets Assets	12250443	usd
CY2021Q4	us-gaap	Assets Assets	10985079	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	679412	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	360964	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49260	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	426823	usd
CY2022Q2	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	25000	usd
CY2021Q4	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	80000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	753672	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	867787	usd
CY2022Q2	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	275000	usd
CY2021Q4	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	235000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1028672	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1102787	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32210944	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32210944	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23974546	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23974546	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3221	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2398	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50166727	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38976263	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33727163	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28086	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17586	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11221771	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12250443	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10985079	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	971182	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1751513	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1919561	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3284618	usd
CY2022Q2	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	36453	usd
CY2021Q2	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	32098	usd
	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	77725	usd
	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	125845	usd
CY2022Q2	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	515090	usd
CY2021Q2	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	477428	usd
	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	1472859	usd
	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	2130076	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	523595	usd
CY2021Q2	us-gaap	Professional Fees ProfessionalFees	700291	usd
	us-gaap	Professional Fees ProfessionalFees	1010296	usd
	us-gaap	Professional Fees ProfessionalFees	1501559	usd
CY2022Q2	hoth	Rent Expenses RentExpenses	15591	usd
CY2021Q2	hoth	Rent Expenses RentExpenses	18898	usd
	hoth	Rent Expenses RentExpenses	29487	usd
	hoth	Rent Expenses RentExpenses	26337	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	237636	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	218791	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	450313	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	399694	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2299547	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	3199019	usd
	us-gaap	Operating Expenses OperatingExpenses	4960241	usd
	us-gaap	Operating Expenses OperatingExpenses	7468129	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2299547	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3199019	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4960241	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7468129	usd
CY2022Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-355184	usd
CY2021Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-57352	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-307682	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-37941	usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-22600	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-22600	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-262	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19508	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41423	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-31493	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-378046	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-76860	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-288859	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-69434	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2677593	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3275879	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5249100	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7537563	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14230	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9063	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	10500	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15537	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2663363	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3266816	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5238600	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7522026	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31034205	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23694499	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27524017	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20702593	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7884493	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15538	usd
CY2022Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1014896	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5985103	usd
CY2022Q2	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	14230	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2677593	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11221771	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	19947799	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-137500	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	768	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	30362	usd
CY2021Q2	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	9063	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3275879	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	16574613	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	592976	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1014896	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5985103	usd
	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	10500	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5249100	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11221771	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4645593	usd
	hoth	Issuance Of Common Stock Common Stock Warrants And Prefunded Warrants IssuanceOfCommonStockCommonStockWarrantsAndPrefundedWarrants	1491600	usd
	hoth	Issuance Of Common Stock Common Stock Warrants And Prefunded Warrantsnet Of Offering Costs IssuanceOfCommonStockCommonStockWarrantsAndPrefundedWarrantsnetOfOfferingCosts	13507632	usd
	hoth	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	572500	usd
	hoth	Issuance Of Common Stock And Warrantnet Of Offering Costs IssuanceOfCommonStockAndWarrantnetOfOfferingCosts	4427501	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	359513	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1156400	usd
	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	15537	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7537563	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	16574613	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5249100	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7537563	usd
	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	61453	usd
	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	896	usd
	hoth	Change In Fair Value Of Investments In Joint Ventures ChangeInFairValueOfInvestmentsInJointVentures	22600	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	592976	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1156400	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-194179	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-584	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-158635	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-47409	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-31492	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	101090	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	52292	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-38762	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	868028	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4359109	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5485046	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	76453	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	7896	usd
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-1553701	usd
	hoth	Sale Of Marketable Securities SaleOfMarketableSecurities	1235696	usd
	hoth	Sale Of Marketable Securities SaleOfMarketableSecurities	1992840	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1159243	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	431243	usd
	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO	13507632	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4427501	usd
	hoth	Proceeds From Issuance Common Stock Net Of Offering Cost ProceedsFromIssuanceCommonStockNetOfOfferingCost	5985103	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	359513	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5985103	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18294646	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5972	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-19105	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2785237	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13240843	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8538270	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2629670	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11317535	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15851408	usd
CY2022Q2	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	8235294	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.85
CY2022Q2	hoth	Additional Purchase Shares AdditionalPurchaseShares	1235294	shares
CY2022Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	6000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-158635	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-47409	usd
CY2022Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-194179	usd
CY2021Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-33914	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-194179	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-584	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12688673	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600299	shares
	hoth	Schedule Of Research And Development Expenses For Licenses Acquired ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,953</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,559</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,225</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,761</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,584</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>University of Cincinnati</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,961</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">36,453</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">32,098</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">77,725</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">125,845</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
CY2022Q2	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	36453	usd
CY2021Q2	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	32098	usd
	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	77725	usd
	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	125845	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	15000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	31000	usd
CY2022Q2	hoth	Accrued License Fee AccruedLicenseFee	275000	usd
CY2022Q2	hoth	Maintenance Fees MaintenanceFees	25000	usd
	hoth	Note Receivable NoteReceivable	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4-Note Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the sublicense agreement dated July 30, 2020 by and between the Company and Isoprene Pharmaceuticals, Inc. (“Isoprene”), the Company made an investment of $50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred stock in a private financing that results in gross proceeds of at least $5 million. “Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization of Isoprene immediately prior to the conversion of the Isoprene Note. In the event a Change of Control occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Qualified Financing, the Isoprene Note may be converted into such number of shares of Isoprene’s common stock equal to the quotient obtained by dividing (i) the balance of the Isoprene Note by (ii) two times the fair market value of a share of Isoprene common stock as set for in the acquisition agreement pertaining to such Change of Control.</p>
CY2020Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	50000	usd
	hoth	Note Receivable Description NoteReceivableDescription	The Isoprene Note matures on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company. In the event a Qualified Financing (as defined below) occurs before the Isoprene Note is repaid in full or the conversion of such note pursuant to a Change of Control (as defined in the Isoprene Note) transaction, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price (as defined below). “Qualified Financing” means the first sale of Isoprene’s convertible preferred stock in a private financing that results in gross proceeds of at least $5 million.
	hoth	Conversion Price Description ConversionPriceDescription	“Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization of Isoprene immediately prior to the conversion of the Isoprene Note.
CY2022Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-180583	usd
CY2021Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-29479	usd
CY2022Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	19578	usd
CY2021Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	6041	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	45132	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	10052	usd
CY2022Q2	hoth	Other Income Nets OtherIncomeNets	-355184	usd
CY2021Q2	hoth	Other Income Nets OtherIncomeNets	-57352	usd
	hoth	Other Income Nets OtherIncomeNets	-307682	usd
	hoth	Other Income Nets OtherIncomeNets	-37941	usd
	hoth	Marketable Securities Mutual Funds MarketableSecuritiesMutualFunds	304327	usd
CY2022Q2	hoth	Investment In Joint Venture InvestmentInJointVenture	387400	usd
CY2022Q2	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	50000	usd
CY2021	hoth	Marketable Securities Mutual Funds MarketableSecuritiesMutualFunds	1892837	usd
CY2021Q4	hoth	Investment In Joint Venture InvestmentInJointVenture	410000	usd
CY2021Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	50000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	410000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-22600	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	387400	usd
CY2022Q2	us-gaap	Fair Value Concentration Of Risk Investment In Federal Home Loan Bank Stock FairValueConcentrationOfRiskInvestmentInFederalHomeLoanBankStock	23000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1671926	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2400000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2801	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1104	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	592976	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1156400	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1697	shares
	hoth	Schedule Of Warrant Activity ScheduleOfWarrantActivity	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 1.5pt">Outstanding as of December 31, 2021</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">10,070,764</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.99</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"> -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2.3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Outstanding as of June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,070,764</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">10,018,093</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.99</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2.0</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3
	us-gaap	Share Based Compensation ShareBasedCompensation	700	usd
	hoth	Unvested Restricted Stock Awards Term unvestedRestrictedStockAwardsTerm	P0Y3M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1321212	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	1295000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.59
	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualIssued	P9Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2616212	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.99
	hoth	Rfl Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 rfl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2616212	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.99
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15538	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30362	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001711786
	hoth	Leases Office Spaces LeasesOfficeSpaces	4500	usd
CY2022Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	16000	usd
CY2021Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	19000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	29000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	26000	usd
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20702593	shares
	hoth	Change In Fair Value Of Investments In Joint Ventures ChangeInFairValueOfInvestmentsInJointVentures		usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities		usd
	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	hoth	Proceeds From Issuance Common Stock Net Of Offering Cost ProceedsFromIssuanceCommonStockNetOfOfferingCost		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	hoth	Share Based Componsation Intrinsic Value Employee Options Issued ShareBasedComponsationIntrinsicValueEmployeeOptionsIssued		usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd

Files In Submission

Name	View Source	Status
0001213900-22-047409-index-headers.html	Edgar Link	pending
0001213900-22-047409-index.html	Edgar Link	pending
0001213900-22-047409.txt	Edgar Link	pending
0001213900-22-047409-xbrl.zip	Edgar Link	pending
f10q0622ex31-1_hoththerap.htm	Edgar Link	pending
f10q0622ex31-2_hoththerap.htm	Edgar Link	pending
f10q0622ex32-1_hoththerap.htm	Edgar Link	pending
f10q0622ex32-2_hoththerap.htm	Edgar Link	pending
f10q0622_hoththerap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hoth-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hoth-20220630_cal.xml	Edgar Link	unprocessable
hoth-20220630_def.xml	Edgar Link	unprocessable
hoth-20220630_pre.xml	Edgar Link	unprocessable
hoth-20220630_lab.xml	Edgar Link	unprocessable
f10q0622_hoththerap_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOTH
Hoth Therapeutics, Inc. Stock $hoth

2022 Q3 Form 10-Q Financial Statement

#000121390022047409 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH Hoth Therapeutics, Inc. Stock $hoth

2022 Q3 Form 10-Q Financial Statement

#000121390022047409 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH
Hoth Therapeutics, Inc. Stock $hoth